ClinVar Miner

Submissions for variant NM_000435.3(NOTCH3):c.239A>G (p.Asp80Gly)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 1
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
ARUP Laboratories, Molecular Genetics and Genomics,ARUP Laboratories RCV001285119 SCV001471483 likely pathogenic none provided 2020-06-09 criteria provided, single submitter clinical testing The NOTCH3 c.239A>G; p.Asp80Gly variant is reported in the literature in a family affected with CADASIL and co-segregated with disease in four affected relatives (Wollenweber 2015). Although the diagnosis of this family was questioned by one group (Rutten 2015), the clinical presentation, MRI profiles, and pathology results from affected family members were judged by other groups to be highly consistent with a specific diagnosis of CADASIL (Wollenweber 2015, Muino 2017). The p.Asp80Gly variant is absent from general population databases (Exome Variant Server, Genome Aggregation Database), indicating it is not a common polymorphism. The aspartate at codon 80 is highly conserved, it occurs in the second EGF-like domain, and computational analyses (SIFT, PolyPhen-2) predict that this variant is deleterious. While most pathogenic NOTCH3 variants occur in exons 2-24 and either create or destroy a cysteine residue within an EGF-like domain (Rutten 2014), the p.Asp80Gly variant does not involve a cysteine residue. However, functional studies suggest the p.Asp80Gly variant protein forms multimers or aggregates at a similar rate to known CADASIL-associated, cysteine-affecting variants (Wollenweber 2015), suggesting it may function through the same mechanism by which other pathogenic NOTCH3 variants are thought to cause disease (Muino 2017). Based on available information, the p.Asp80Gly variant is considered to be likely pathogenic. References: Muino E et al. Systematic Review of Cysteine-Sparing NOTCH3 Missense Mutations in Patients with Clinical Suspicion of CADASIL. Int J Mol Sci. 2017 Sep 13;18(9). pii: E1964. Rutten JW et al. Interpretation of NOTCH3 mutations in the diagnosis of CADASIL. Expert Rev Mol Diagn. 2014 Jun;14(5):593-603. Rutten J et al. Letter by Rutten et al Regarding Article, "Cysteine-Sparing CADASIL Mutations in NOTCH3 Show Proaggregatory Properties In Vitro". Stroke. 2015;46(6):e153. Wollenweber FA et al. Cysteine-sparing CADASIL mutations in NOTCH3 show proaggregatory properties in vitro. Stroke. 2015;46(3):786-792.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.